MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
Division of Diagnostic Nuclear Medicine, Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
PET Clin. 2022 Jul;17(3):399-413. doi: 10.1016/j.cpet.2022.04.001.
Hormone-sensitive breast cancer, which demonstrates hormone receptor positivity, accounts for approximately 75% of newly diagnosed breast cancer. 2-[18F]-Fluoro-2-deoxy-glucose is the nonspecific radiotracer of glucose metabolism as opposed to specific receptor based tracers like 16α-[18F]-fluoro-17β-estradiol and [18F]-fluoro-furanyl-norprogesterone, which provide essential information about receptor status in the management of hormonally active malignancies. The complementary information provided by (a) 2-[18F]-fluoro-2-deoxy-glucose imaging for staging and prognostication along with (b) analyzing the hormonal receptor status with receptor-based PET imaging in breast cancer can optimize tumor characterization and influence patient management.
激素敏感性乳腺癌，表现为激素受体阳性，约占新诊断乳腺癌的 75%。2-[18F]-氟-2-脱氧葡萄糖是葡萄糖代谢的非特异性放射性示踪剂，而不是 16α-[18F]-氟-17β-雌二醇和[18F]-氟-呋喃基-诺孕酮等基于特异性受体的示踪剂，后者提供了激素活性恶性肿瘤受体状态的重要信息。（a）2-[18F]-氟-2-脱氧葡萄糖成像用于分期和预后，以及（b）用受体 PET 成像分析乳腺癌中的激素受体状态，这两者提供的互补信息可以优化肿瘤特征并影响患者管理。
